risankizumab   Click here for help

GtoPdb Ligand ID: 8922

Synonyms: ABBV-066 | BI 655066 | BI-655066 | risankizumab-rzaa | Skyrizi®
Approved drug Immunopharmacology Ligand
risankizumab is an approved drug (Japan, FDA & EMA (2019))
Compound class: Antibody
Comment: Risankizumab (research code BI 655066) is a humanised monoclonal antibody targeting interleukin 23A (IL-23A) [11]. It was developed through collaboration between Boehringer Ingelheim and AbbVie for the treatment of autoinflammatory diseases.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-23A Primary target of this compound Hs Antibody Binding >11.0 pKd - 11
⤷ pKd >11.0 (Kd <1x10-11 M) [11]